[go: up one dir, main page]

WO2023172989A3 - Agonistes et antagonistes du récepteur epo - Google Patents

Agonistes et antagonistes du récepteur epo Download PDF

Info

Publication number
WO2023172989A3
WO2023172989A3 PCT/US2023/063996 US2023063996W WO2023172989A3 WO 2023172989 A3 WO2023172989 A3 WO 2023172989A3 US 2023063996 W US2023063996 W US 2023063996W WO 2023172989 A3 WO2023172989 A3 WO 2023172989A3
Authority
WO
WIPO (PCT)
Prior art keywords
epo
epor
antibodies
antagonists
receptor agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2023/063996
Other languages
English (en)
Other versions
WO2023172989A2 (fr
Inventor
Bo Yu
Edgar G. Engleman
Xiangyue ZHANG
David Kung-Chun CHIU
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunedge Inc
Leland Stanford Junior University
Original Assignee
Immunedge Inc
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunedge Inc, Leland Stanford Junior University filed Critical Immunedge Inc
Priority to EP23767673.9A priority Critical patent/EP4490187A2/fr
Priority to CA3255594A priority patent/CA3255594A1/fr
Priority to IL315499A priority patent/IL315499A/en
Priority to CN202380039511.1A priority patent/CN119365486A/zh
Priority to KR1020247033372A priority patent/KR20250007062A/ko
Priority to JP2024553795A priority patent/JP2025508129A/ja
Priority to US18/844,732 priority patent/US20250129170A1/en
Priority to AU2023232105A priority patent/AU2023232105A1/en
Publication of WO2023172989A2 publication Critical patent/WO2023172989A2/fr
Publication of WO2023172989A3 publication Critical patent/WO2023172989A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des analogues d'EPO, des anticorps anti-EPOR, des anticorps anti-EPO, et des fragments de ceux-ci qui se lient spécifiquement à l'hétéro-EPOR ou à l'homo-EPOR ou à l'EPO avec une affinité élevée. L'invention concerne également des EPO modifiés. Les analogues d'EPO, les anticorps anti-EPOR, les anticorps anti-EPO et/ou les EPO modifiés peuvent être utilisés pour traiter des patients.
PCT/US2023/063996 2022-03-08 2023-03-08 Agonistes et antagonistes du récepteur epo Ceased WO2023172989A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP23767673.9A EP4490187A2 (fr) 2022-03-08 2023-03-08 Agonistes et antagonistes du récepteur epo
CA3255594A CA3255594A1 (fr) 2022-03-08 2023-03-08 Agonistes et antagonistes du récepteur epo
IL315499A IL315499A (en) 2022-03-08 2023-03-08 EPO receptor agonists and antagonists
CN202380039511.1A CN119365486A (zh) 2022-03-08 2023-03-08 Epo受体激动剂和拮抗剂
KR1020247033372A KR20250007062A (ko) 2022-03-08 2023-03-08 Epo 수용체 효능제 및 길항제
JP2024553795A JP2025508129A (ja) 2022-03-08 2023-03-08 Ｅｐｏ受容体アゴニストおよびアンタゴニスト
US18/844,732 US20250129170A1 (en) 2022-03-08 2023-03-08 Epo receptor agonists and antagonists
AU2023232105A AU2023232105A1 (en) 2022-03-08 2023-03-08 Epo receptor agonists and antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263317943P 2022-03-08 2022-03-08
US63/317,943 2022-03-08

Publications (2)

Publication Number Publication Date
WO2023172989A2 WO2023172989A2 (fr) 2023-09-14
WO2023172989A3 true WO2023172989A3 (fr) 2023-12-07

Family

ID=87935923

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2023/063996 Ceased WO2023172989A2 (fr) 2022-03-08 2023-03-08 Agonistes et antagonistes du récepteur epo
PCT/US2023/063997 Ceased WO2023172990A2 (fr) 2022-03-08 2023-03-08 Agonistes et antagonistes du récepteur epo

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2023/063997 Ceased WO2023172990A2 (fr) 2022-03-08 2023-03-08 Agonistes et antagonistes du récepteur epo

Country Status (9)

Country Link
US (2) US20250129147A1 (fr)
EP (1) EP4490187A2 (fr)
JP (1) JP2025508129A (fr)
KR (1) KR20250007062A (fr)
CN (1) CN119365486A (fr)
AU (1) AU2023232105A1 (fr)
CA (1) CA3255594A1 (fr)
IL (1) IL315499A (fr)
WO (2) WO2023172989A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202300015063A1 (it) * 2023-07-18 2025-01-18 Andremacon S R L Metodo per potenziare l'efficacia dell'immunoterapia e potenziare la risposta immunitaria dell'ospite
CN117017974A (zh) * 2023-09-12 2023-11-10 南京鼓楼医院 水飞蓟宾在制备治疗系统性红斑狼疮的药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022025204A1 (fr) * 2020-07-30 2022-02-03 エポメッド株式会社 Traitement d'une maladie par un antagoniste d'epor

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1169352A4 (fr) * 1999-04-14 2005-05-04 Smithkline Beecham Corp Anticorps du recepteur d'erythropoietine
EP1459762B1 (fr) * 2001-11-02 2008-07-02 Yoshiko Yasuda Utilisation de l'emp9 pour la prévention de maladies proliferatives des organes
US7160697B2 (en) * 2002-08-21 2007-01-09 Duke University Use of novel cytokine receptors as biomarkers and therapeutic targets in human cancer
US9878056B2 (en) * 2012-04-02 2018-01-30 Modernatx, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022025204A1 (fr) * 2020-07-30 2022-02-03 エポメッド株式会社 Traitement d'une maladie par un antagoniste d'epor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANTARELLI ET AL.: "Erythropoietin, a multifaceted protein with innate and adaptive immune modulatory activity", AM J TRANSPLANT, vol. 19, 2019, pages 2407 - 2414, XP072344308, DOI: 10.1111/ajt.15369 *
LEE TZONG-SHYUAN, LU KUO-YUN, YU YUAN-BIN, LEE HSUEH-TE, TSAI FENG-CHUAN: "β Common Receptor Mediates Erythropoietin-Conferred Protection on OxLDL-Induced Lipid Accumulation and Inflammation in Macrophages", MEDIATORS OF INFLAMMATION., RAPID COMMUNICATION OF OXFORD LTD., OXFORD., GB, vol. 2015, 1 January 2015 (2015-01-01), GB , pages 1 - 13, XP093119515, ISSN: 0962-9351, DOI: 10.1155/2015/439759 *
WEI SPENCER C.; LEVINE JACOB H.; COGDILL ALEXANDRIA P.; ZHAO YANG; ANANG NANA-AMA A.S.; ANDREWS MILES C.; SHARMA PADMANEE; WANG JI: "Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade", CELL, ELSEVIER, AMSTERDAM NL, vol. 170, no. 6, 10 August 2017 (2017-08-10), Amsterdam NL , pages 1120, XP085189776, ISSN: 0092-8674, DOI: 10.1016/j.cell.2017.07.024 *

Also Published As

Publication number Publication date
WO2023172989A2 (fr) 2023-09-14
CA3255594A1 (fr) 2023-09-14
WO2023172990A2 (fr) 2023-09-14
US20250129147A1 (en) 2025-04-24
JP2025508129A (ja) 2025-03-21
EP4490187A2 (fr) 2025-01-15
KR20250007062A (ko) 2025-01-13
US20250129170A1 (en) 2025-04-24
IL315499A (en) 2024-11-01
WO2023172990A3 (fr) 2023-11-09
AU2023232105A1 (en) 2024-10-17
CN119365486A (zh) 2025-01-24

Similar Documents

Publication Publication Date Title
WO2023172989A3 (fr) Agonistes et antagonistes du récepteur epo
SG160224A1 (en) Novel peptides that bind to the erythropoietin receptor
WO2020072821A3 (fr) Protéines de fusion fc hétérodimères d'il -12
JO2828B1 (en) Anti-Hepsidine antibodies and their uses
WO2013184960A3 (fr) Protéines chimères du facteur de croissance des fibroblastes 23 et méthodes d'utilisation
EP4574208A3 (fr) Agonistes du récepteur de l'hormone thyroïdienne et utilisations associées
ZA202206437B (en) Claudin18.2 binding moieties and uses thereof
WO2022040506A3 (fr) Compositions de nanocorps et leurs procédés d'utilisation
EP2283860A3 (fr) Utilisation d'interleukine 33 (il-33) et du complexe recepteur il-33
BR0008688A (pt) Antagonistas de il-18 recombinantes utilizáveis no tratamento de distúrbios mediados por il-18
MY139055A (en) Lyophilised preparation containing antibodies to the egf receptor
EA201201047A1 (ru) Способы и композиции, в которых применяют слитые полипептиды fgf 23
WO2006062685A3 (fr) Nouveaux peptides se liant au recepteur de l'erythropoietine
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
DE69930872D1 (de) Antikörper gegen verkürzten vegf-d und deren verwendungen
EP4495136A3 (fr) Méthodes et compositions pour le traitement de troubles angiogéniques à l'aide d'agents anti-vegf
EP1383919A4 (fr) Methodes et compositions permettant d'utiliser un polypeptide a chaine invariant de classe ii mhc en tant que recepteur du facteur d'inhibition de la migration des macrophages
NZ749578A (en) Anti-met antibodies and uses thereof
WO2021231800A3 (fr) Anticorps anti-hémojuveline (hjv) de traitement de l'anémie de maladies chroniques
MX2022008659A (es) Moléculas de anticuerpos específicos contra c5ar1 y usos de estas.
BR112021026389A2 (pt) Métodos e materiais para expansão direcionada de células t reguladoras
WO2011056954A8 (fr) Polypeptides d'haemophilus parasuis et leurs procédés d'utilisation
MX2025010585A (es) Trans-cicloocteno con enlazador t mejorado
WO2005101838A8 (fr) Utilisation de derives de piperazinylpiperidine comme antagonistes de recepteurs de chimiokines
WO2022221844A3 (fr) Récepteurs antigéniques chimériques améliorés et leurs utilisations

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767673

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 315499

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2024553795

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: AU2023232105

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 815266

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 202417076016

Country of ref document: IN

Ref document number: 2023767673

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2023767673

Country of ref document: EP

Effective date: 20241008

ENP Entry into the national phase

Ref document number: 2023232105

Country of ref document: AU

Date of ref document: 20230308

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 11202406210W

Country of ref document: SG

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23767673

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 202380039511.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 202380039511.1

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 18844732

Country of ref document: US